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BMl-1 expression increases in oral 
leukoplakias and correlates with cell 
proliferation
Oral leukoplakia (OL) is a white lesion of an indeterminate risk not 
related to any excluded (other) known diseases or disorders that carry no 
increased risk for cancer. Many biological markers have been used in an 
attempt to predict malignant transformation; however, no reliable markers 
have been established so far. Objective: To evaluate cell proliferation and 
immortalization in OL, comparing non-dysplastic (Non-dys OL) and dysplastic 
OL (Dys OL). Methodology: This is a cross-sectional observational study. 
Paraffin-embedded tissue blocks of 28 specimens of Non-dys OL, 33 of Dys 
OL, 9 of normal oral mucosa (NOM), 17 of inflammatory hyperplasia (IH), 
and 19 of oral squamous cell carcinomas (OSCC) were stained for Ki-67 and 
BMI-1 using immunohistochemistry. Results: A gradual increase in BMI-1 
and K-i67 expression was found in oral carcinogenesis. The immunolabeling 
for those markers was higher in OSCC when compared with the other 
groups (Kruskal-Wallis, p<0.05). Ki-67 expression percentage was higher 
in OL and in IH when compared with NOM (Kruskal-Wallis/Dunn, p<0.05). 
Increased expression of BMI-1 was also observed in OL when compared 
with NOM (Kruskal-Wallis/Dunn, p<0.05). No differences were observed in 
expression of both markers when non-dysplastic and dysplastic leukoplakias 
were compared. A significant positive correlation between Ki-67 and BMI-1 
was found (Spearman correlation coefficient, R=0.26, p=0.01). High-grade 
epithelial dysplasia was associated with malignant transformation (Chi-
squared, p=0.03). Conclusions: These findings indicate that BMI-1 expression 
increases in early oral carcinogenesis and is possibly  associated with the 
occurrence of dysplastic changes. Furthermore, our findings indicate that 
both Ki-67 and BMI-1 are directly correlated and play a role in initiation and 
progression of OSCC.
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Introduction
Oral leukoplakia (OL) is a lesion with a risk of 
malignant transformation ranging from 0.13% to 
17.5%.1 Histopathologically, OL is characterized by 
a variety of epithelial changes, including dysplasia. 
The presence of epithelial dysplasia is considered the 
most important predictive factor for OL prognosis.1-3
Although many biological markers have been 
explored, no reliable ones have yet been established 
for predicting malignant transformation of OL, thus 
necessitating additional studies to increase our 
knowledge of the biological processes underlying OL 
and oral carcinogenesis.4 Ki-67 is a nuclear protein 
expressed in the G1, S, G2, and M phases of the cell 
cycle, and its expression reflects the total growth 
fraction in tissues.5 Ki-67 expression correlates with the 
severity of epithelial dysplasia and histological grading 
of oral squamous cell carcinoma (OSCC).6,7 Another 
protein named BMI-1, which mediates gene silencing 
by regulating chromatin structure,8,9 plays a central 
role in cell cycle regulation and cell immortalization, 
as well as cell senescence and epithelial-mesenchymal 
transition (EMT).10,11 BMI-1 is associated with the 
initiation and progression of various tumors, including 
oropharyngeal,10 nasopharyngeal,11 and prostate12 
cancers. Furthermore, increased BMI-1 expression 
was found in bronchial premalignant lesions as well 
as squamous cell carcinoma (SCC), indicating that its 
expression in neoplastic cells may be an early event 
in lung carcinogenesis.13 BMI-1 is also overexpressed 
in OSCC cells when compared with normal oral 
mucosa cells and has been presumed to influence 
proliferation and immortalization of epithelial cells in 
oral carcinogenesis.14
This study aimed to evaluate cell proliferation 
and immortalization in OL by studying Ki-67 and 
BMI-1 expression in non-dysplastic (Non-dysOL) and 
dysplastic (DysOL) cases.
Methodology
Patients and tissue specimens
Ninety-eight cases of OL reported between 2000 
and 2014 were selected for this study. Tissue samples 
were obtained from the archives of the Laboratories 
of Pathology of the Hospital de Clínicas de Porto 
Alegre and the School of Dentistry of the Federal 
University of Rio Grande do Sul considering the clinical 
impression of leukoplakia. The study protocol was 
approved by Human Research Ethics Committee (CAAE 
26759114900005327).
Information on demographics, risk factors, 
clinical presentation, treatment, and prognosis are 
shown in Table 1. Moreover, histological slides were 
revised to exclude cases incompatible with OL and 
cases with incomplete information in medical records 
or insufficient material for sampling. Descriptive 
histopathological diagnosis such as atrophy, acanthosis, 
epithelial hyperplasia, hyperkeratosis, and epithelial 
dysplasia were considered microscopic features of a 
clinical diagnosis of leukoplakia. After selection, the 
medical records were evaluated to confirm the clinical 
hypothesis and the final diagnosis of leukoplakia after 
clinical and microscopic correlation. Cases of in situ 
carcinoma were excluded. After that, 61 cases of OL 
were included for analysis (Figure 1). Nine cases of 
normal oral mucosa (NOM) obtained during surgical 
removal of unerupted third molars and, 17 cases of 
inflammatory hyperplasia (IH), and 19 cases of OSCC 
were used as comparison groups. IH cases were 
included as a reference for benign lesions that show 
an increased cell proliferation without the potential for 
malignant transformation.
Clinical and follow up data
Clinical data regarding lesion location, clinical 
presentation and lesion size were obtained from 
the clinical forms of patients seen in the School of 
Dentistry. Patients who did not present new lesions 
and maintained the clinical characteristics and/or 
OSCC development during the follow-up period were 
considered as having good prognosis. Patient who 
presented new lesions, increased lesion size, changes 
in surface and/or color, as well as those who developed 
OSCC were considered as having poor prognosis. 
Histopathological analysis
All selected samples were fixed in 10% neutral 
formalin and embedded in paraffin. Five-micrometer 
H&E (hematoxylin and eosin) stained sections 
were blindly reviewed by two pathologists (V.C.C. 
and I.P.K.). The epithelial dysplasia in OL samples 
was graded according to the criteria and definition 
proposed by Reibel, et al.15 (2017) and Kujan, et al.16 
(2006). A consensus was reached in cases that were 
graded differently by the two pathologists.
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Immunohistochemistry
T i s s u e  s e c t i o n s  w e r e  s u b j e c t e d  t o 
immunohistochemical staining for BMI-1 and Ki-67 
antigens. Shortly after, blocks were sectioned (3 
μm) and placed on silanized slides. The slides were 
subsequently deparaffinized in xylene and hydrated 
in descending grades of ethanol. Antigen retrieval 
for Ki-67 was performed for 18 h in low pH solution 
in a 90°C water bath, and for BMI-1, Tris-HCl buffer 
(pH 8.5) for 20 min at 98°C was used for the water 
bath. The slides were then incubated with the primary 
antibodies: Ki-67 (MIB-1, DAKO, 1:50, 1 h) and 
BMI-1 (ab14389, Abcam, 1:100, 1 h). The EnVision 
(DakoCytomation, Carpinteria, CA, USA) was used 
as the detection system. The sections were then 
incubated with diaminobenzidine tetrahydrochloride 
(DAB, Novocastra, Newcastle, UK) and counterstained 
with Mayer’s hematoxylin. The primary antibody was 
omitted for the negative control. The human appendix 
and reactive lymph node tissue were used as positive 
controls for BMI-1 and Ki-67, respectively. Only nuclear 
brown staining was considered as positive marking, 
regardless of the color intensity.17,18
Immunostaining evaluation
Images of the selected fields were captured 
using a conventional light microscope (CX41RF 
model, Olympus Latin America, Inc., Miami, Florida, 
USA) coupled to a camera (QColor 5, Coolet, RTV, 
Olympus Latin America, Inc., Miami, Florida, USA) 
and connected to a computer (Dimension 5150, Dell, 
Porto Alegre, RS, Brazil). Images were analyzed using 
the QCapture software program (Quantitative Imaging 
Corporation, Inc., Surrey, DC, Canada, version 2.81). 
Immunohistochemical evaluation was performed under 
high-power magnification (×400). Nuclear staining 
was considered for positivity, regardless of staining 
intensity. Ki-67 were counted and classified based 
on Gonzalez-Moles, et al.5 (2000). The quantitative 
analysis involved the analysis of images of the slides 
using the same aforementioned imaging system. The 
labeling index (LI) was determined by the percentage 
of labeled nuclei per 1000 cells of all specimens of each 
group.5 BMI-1 was analyzed semi-quantitatively using 
scores based on the percentage of positive cells. To 
each case was assigned a score as follows: 1 (up to 
50% positive cells - low), 2 (50 – 80% - moderate), 
and 3 (over 80% - high).19
Statistical analysis
The Kruskal-Wallis test, followed by Dunn’s test, 
was used for multiple comparisons and the Chi-
square test was used for comparisons of scores 
distribution among the groups. Student t/ANOVA 
and Mann-Whitney/Kruskal Wallis tests were used 
to assess the influence of OL characteristics on Ki-
67 and BMI-1 expression, respectively. Spearman’s 
correlation analysis was conducted to determine the 
relationship between BMI-1 and Ki-67 expression. 
The SPSS Statistics software, 18.0 Version, was used 
for statistical analysis, and p value threshold used 
was 5%.
Results
Demographic and clinical characteristics
Table 1 shows the demographic and clinical 
characteristics of the OL and OSCC patients. The 
cases were divided into two groups, namely “tongue 
or floor of the mouth” and “other sites”, according 
to the lesion site.20 The tongue or floor of the mouth 
Figure 1- Flowchart of sampling strategy, depicting the criteria to select the study sample. After revision, the cases in which oral leukoplakia 
was confirmed were subjected to a strict evaluation to define if the amount of tissue was enough to prepare the required number of 
histological sections. Cases with previous history of squamous cell carcinoma were discarded
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group had a significantly higher percentage of OSCC 
cases (Student’s t test, p=0.02) when compared with 
OL cases. Regarding prognosis, twenty-two (55.0%) 
patients had good prognosis and 18 (45.0%), poor 
prognosis. 
Table 2 shows the characteristics of OL without and 
with OSCC development during the follow-up period 
ranging from 12 to 156 months (56.9±33.0). Follow-
up information was not available in 21 cases (34.4%), 
whereas it was available for 40 OL patients (65.5%). 
Four of the 40 OL patients (10.0%) developed OSCC, 
resulting in a 2.1% annual malignant transformation 
OL  OSCC p
CHARACTERISTIC
All patients, no.(%) 61 (76.25) 19 (23.75)
Age, years 
Mean 58.0 59.4 0.65* 
Standard deviation 12.8  10.9
Range (minimum-maximum) 26-81  39-82
Gender, no(%) 
Female 26 (42.6) 6 (31.6%) 0.56** 
Male 35 (57.4) 13 (68.4%) 
Tobacco habits, no(%) 
Never 8 (16.3) 2 (13.3%) 0.71** 
Past and present 41 (83.7) 13 (86.7%) 
Unknown 12 4
Alcohol consumption, no(%) 
Never 8 (17.4) 3 (25.0%) 0.68** 
Past and present 38 (82.6) 9 (75.0%) 
 Unknown 15 7
Location, no(%) 
Tongue / floor of the mouth 19 (31.6) 12 (63.2%) 0.02** 
Other locations 41 (68.4) 7 (36.8%) 
Unknown 1 0
Clinical type, no(%) 
Homogeneous 32 (60.4) _ _
Non homogeneous 21 (39.6) _
 Unknown 8 _
Lesion size, no(%) 
<2 cm 30 (60.0) _ _
≥2 cm 20 (40.0) _
Unknown 11 _
TNM, no(%) 
I/II _ 5(27.8%) _
III/IV  _ 13(72.2%)
Unknown _ 1
Presence of epithelial dysplasia, no(%) 
No 28 (45.9) _ _
Yes 33 (54.1) _
Grade of epithelial dysplasia, no (%)
Absent 28 (45.9) _ _
Low grade 22 (36.1) _
High grade 11 (18.0) _
*Student’s t test; **Chi-square test
Table 1- Demographic and clinical characteristics of the OL and OSCC patient
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rate. Of these 4 patients, 3 (75.0%) patients 
underwent malignant transformation in the tongue or 
floor of the mouth and exhibited a high grade dysplasia 
(Chi-square test, p<0.01).
Immunohistochemical analysis
Ki-67 expression increases in IH, OL and OSCC 
(Table 3).
Ki-67 immunolabeling data is shown in Figure 2. 
There was a gradual increase in Ki-67 expression 
(ANOVA/Tukey, p<0.01) through NOM (10.2%), IH 
(29.4%), Non-dysOL (33.1%), DysOL (36.3%) and 
OSCC (62.8%). Moreover, cell proliferation was higher 
(ANOVA/Tukey, p<0.01) through NOM to OSCC. 
Comparisons among different grades of epithelial 
dysplasia showed no statistically significant differences 
(Kruskal Wallis, p>0.05). Representative images of 
Ki-67 immunolabeling are shown in Figure 2.
BMI-1 expression increases in IH, OL and OSCC 
(Table 3).
Increasing positivity was observed for BMI-1 
through NOM (1.7%), IH (2.1%), Non-dysOL (2.4%), 
DysOL (2.5%) and OSCC (2.8%), agreeing with the Ki-
67 expression pattern. Non-dysOL cases showed lower 
BMI-1 immunolabeling when compared with the DysOL 
cases, although this difference was not statistically 
significant. However, the means were statistically 
higher (Kruskal Wallis, p<0.01) in OL when compared 
with that in NOM, and in OSCC, when compared with 
that in NOM, IH and OL. Representative images of 
BMI-1 immunolabeling are shown in Figure 2.
Correlation between BMI-1 and Ki-67 expression
Spearman’s correlation coefficients were estimated 
to determine if BMI-1 expression could be associated 
with changes in cell proliferation. BMI-1 expression 
directly correlated with Ki-67 expression (Spearman’s 
correlation, R=0.26, p=0.01).
OL patients without OSCC 
development 




Mean (SD)  56.3 (13.0) 52.7 (15.9) 0.61* 
Min-Max 26-79 31-68 
Gender 
Male 23 (63.9) 2 (50.0) 0.62** 
Female 13 (36.1) 2 (50.0)
Location 
Tongue/floor of the mouth 11 (30.6) 3 (75.0) 0.11* 
Others  25 (69.4) 1 (25.0) 
Clinical type 
Homogeneous 20 (64.5) 1 (33.3) 0.54** 
Non-homogeneous 11 (35.5) 2 (66.7)
 Unknown 5 1
Lesion size 
<2cm 17 (54.8) 1 (50.0) 1.00** 
≥2cm 14 (45.2) 1 (50.0)
Unknown 5 2
Presence of epithelial dysplasia 
No 17 (47.2)    1 (25.0) 0.01** 
Yes 19 (52.8)  3 (75.0) 
Epithelial dysplasia grade 
Absent 18 (50.0) 1 (25.0) 0.03**
Low risk 12 (33.3) 0 (0.0)
High risk 6 (16.7) 3 (75.0)
*Student’s t test; **Chi-square test
Table 2- Demographic and clinical characteristics of the OL with and without OSCC development
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Association of Ki-67 and BMI-1 immunolabeling 
with OL c l in ica l  character is t ics  and 
histopathological changes (Table 4)
Higher Ki-67 and BMI-1 expression was observed 
in lesions in the tongue and floor of the mouth, 
epithelial dysplasia, OSCC development and poor 
clinical evolution; however, the associations were not 
statistically significant. 
Figure 2- Gradual increase of Ki-67 and BMI-1 expression is observed from to normal oral mucosa (NOM) to oral squamous cell 
carcinoma (OSCC). Representative photomicrographs of NOM, inflammatory hyperplasia (IH), non-dysplastic oral leukoplakia (Non-dys 
OL), dysplastic oral leukoplakia (Dys OL) and OSCC. Original magnification ×400
NOM IH Non-dys OL Dys OL SCC p
Ki-67 immunolabeling
Mean 10.2A 29.4B 33.1B 36.3B 62.8C <0.01*
SD 3.0 8.9 11.1 15.2 16.6
BMI-1 immunolabeling
Mean 1.7A 2.1B 2.4B 2.5B 2.8C <0.01**
SD 0.5 0.9 0.7 0.7 0.4
* ANOVA/Tukey, **Kruskal-Wallis test/Dunn. Means followed by different uppercase letters are different from each other
Table 3- Percentage of immunopositive cells for Ki-67 and BMI-1 in normal oral mucosa (NOM), inflammatory hyperplasia (IH), and oral 
leukoplakia (OL)
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Discussion
Oral carcinogenesis is a complex process resulting 
from various genetic and epigenetic changes. BMI-1 
overexpression in OSCC cells has been suggested to 
be associated with an increased cell proliferation14 and 
to be a predictive of tumorigenesis.21,22 Interestingly, 
statistically significant changes were observed in 
early stages of carcinogenesis.21,22 Moreover, BMI-1 
immunolabeling levels were directly associated with 
cell proliferation in epithelium during carcinogenesis.23 
To the best of our knowledge, this study is the first 
to assess Ki-67 and BMI-1 expression in OL.19 As 
expected, the expression of these markers was 
increased in OL when compared with NOM.
BMI-1 is involved in the transcriptional repression 
of Hox genes, thus affecting stem cell self-renewal, 
embryonic development, and proliferation.24,25 Our 
results show that BMI-1 expression increases during 
carcinogenesis. However, BMI-1 immunolabeling 
analysis showed no differences between OL and IH. 
OL presented a higher and statistical positivity of 
BMI-1 when compared with NOM. Our results agrees 
with those of Kang, et al.14 (2007), who reported 
that increased BMI-1 expression was associated with 
dysplastic changes during oral carcinogenesis. The 
role of BMI-1 in EMT demonstrated in previous studies 
with breast cancer cells further support our findings. 
Moreover, BMI-1 overexpression in cancer cells has 
been reported to activate PI3K/AKT signaling pathway, 
and induce cell migration and metastasis.26,27 
Liu, et al.28 (2012) found that BMI-1 expression 
was associated with the development of oral cancer in 
patients with OL, suggesting that immunohistochemical 
marker could be used as a predictor of OL transformation. 
In that study, approximately 13% of 135 OL patients 
demonstrating BMI-1 positivity developed OSCC 
when compared with 10.3% patients negative for 
BMI-1. In our study, 10.0% of OL patients who were 
followed-up developed OSCC. In these patients, the 
presence of high grade dysplasia was found to be a 
predictor for OSCC development. The same group 
of patients displayed an increased Ki-67 and BMI-
1 expression; however, this was not statistically 
significant. Regarding the lesion site, three of the 
Ki-67(%) BMI-1 (score)
Mean(SD) p Mean(SD) p
Location 
Tongue / floor of the mouth 23.1 (12.4) 0.69a 2.6 (0.6) 0.42b
Other locations 38.3 (11.5) 2.4 (0.7)
Clinical type 
Homogeneous 32.3 (14.5)  0.24a 2.5 (0.7) 0.84b
Non-homogeneous 27.7 (12.8) 2.5 (0.6)
Lesion size 
<2 cm 24.7 (12.9) 0.39a 2.4 (0.7) 0.52b
≥2 cm 28.4 (13.3) 2.6 (0.6)
Presence of epithelial dysplasia 
No 33.1 (11.1) 0,58a 2.4 (0.7) 0.44b
Yes 36.3 (15.2) 2.5 (0.7)
Grade of epithelial dysplasia 
Absent 33.1 (11.1) 0.08c 2.4 (0.1) 0.37d
Low grade 33.0 (15.7) 2.4 (0.2)
High grade 43.0 (12.4) 2.7 (0.1)
OSCC development 
No 25.4 (12.6) 0.24a 2.3 (0.7) 0.26b
Yes 33.5 (14.9) 2.6 (1.0)
Clinical evolution 
Good 24.7 (12.9) 0.39a 2.3 (0.6) 0.23b
Poor 24.8 (13.3) 2.5 (0.8)
aStudent’s t test; bMann Whitney’s test; cANOVA;  dKruskal-Wallis
Table 4- Clinical and histopathological characteristics in OL cases and the association with the expression of Ki-67 and BMI-1
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four lesions were located in the tongue/floor of the 
mouth, reinforcing that lesions at these sites present 
a more aggressive behavior.20 The annual malignant 
transformation rate observed in our study agrees with 
that reported by other recent studies.20 An increased 
cell proliferation is well known to be one of the main 
events of carcinogenesis.29,30 Our findings showed an 
increased percentage of Ki-67 positive cells in Non-
dysOL and DysOL. Moreover, cell proliferation was 
higher in OSCC when compared with NOM.
Although the immunoexpression of Ki-67 was 
slightly higher in DysOL than in Non-dysOL, the 
difference was not statistically significant, as found 
in previous studies.30,31 Furthermore, the same study 
showed that Ki-67 expression was progressively higher 
depending on the degree of epithelial dysplasia.32 
Therefore, our findings reinforce that Ki-67 expression 
is a valuable predictive marker for oral leukoplakia 
progression, reinforcing the presence of mitosis in the 
upper half of the epithelium as an important criterion 
in the morphological analysis, as recommended by 
previous studies.6,33
The other important result was the significant 
correlation found between Ki-67 and BMI-1 
immunolabeling. This may be attributed to the role 
of BMI-1 in the regulation of cell proliferation by 
suppressing INK4a expression, a locus that triggers 
senescence in human somatic cells.34 Therefore, 
the switch between differentiation and epithelial-
mesenchymal transition, which depends on genetic 
and epigenetic events, is modulated by the control 
of cell growth, survival, angiogenesis, and motility. 
The balance of cross-talk between these signaling 
pathways is the basis for acquiring a malignant 
phenotype and progression to OSCC. Despite the large 
number of studies on this subject, the knowledge 
about individual factors must be improved to develop 
strategies for cancer prevention.35
To the best of our knowledge, this study is the 
first to report the correlation between Ki-67 and 
BMI-1 expression in OL. Based on the results, cell 
proliferation and changes towards epithelial-to-
mesenchymal transition are likely related events 
during carcinogenesis. The increased expression of 
BMI-1 in the early stages of development of oral 
carcinogenesis indicates its potential use as a marker 
of preneoplastic oral lesions. 
Conclusion
The findings of this study indicate that BMI-1 
expression increases in early oral carcinogenesis 
and that it may be associated with the occurrence of 
dysplastic changes. Furthermore, our findings indicate 
that both Ki-67 and BMI-1 are directly correlated and 
possibly play a role in initiation and progression of 
OSCC.
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